IRB #
STUDY00022463
Title
[NCI CIRB] A021804 - A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Principal Investigator
Michael Heinrich
Study Purpose
This study is being done to find out if we can lower the chance of your pheochromocytoma or paraganglioma from growing or spreading by comparing two treatments of olaparib plus temozolomide vs. temozolomide. Also, we hope to find out if this approach is better or worse than the usual approach.
Medical Condition(s)
Pheochromocytoma and Paraganglioma
Eligibility Criteria
Histologically proven advanced pheochromocytoma or paraganglioma
Prior treatment with other chemotherapy, radiotherapy, or surgery must be completed >28 days prior to registration.
Prior treatment with radiolabeled MIBG must be completed >12 weeks prior to registration.
Prior treatment with antibiotics must be completed >7 days prior to registration.
No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor.
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation.
>18 years of age
Performance status of 0-2
Age Range
18 - 99
Healthy Volunteers Needed
No
Duration of Participation
5 years
Minors Included
No
Contact
Knight Information Line - trials@ohsu.edu or 503-494-1080
Sponsor
Alliance
Recruitment End
01/02/2023
Compensation Provided
No
Go Back